Assessment of psychedelic--induced states: Norwegian translation and adaptation of the revised Mystical Experience Questionnaire (MEQ-30)
Kristoffer Andreas Aamodt Andersen, Bjørn Holmøy, Lowan H. Stewart
Journal of Psychedelic Studies July 12, 2024 DOI: 10.1556/2054.2024.00346 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Translation and adaptation study Peer reviewed |
|---|---|
| Sample size | 12 |
| Population | Psychedelic users and experts |
| Topics | Mysticism Psilocybin Mystical experience |
| Keywords | Norwegian Debriefing Clinical psychology Applied psychology |
| Citations | 1 |
| Key points | A Norwegian version of the MEQ30 was successfully translated and culturally adapted for use in future Norwegian trials. |
Abstract
Abstract Background Previous international clinical trials have indicated that mystical experiences resulting from the consumption of classic psychedelic drugs, such as psilocybin, may represent a subjective psychological mechanism of action associated with therapeutic effects for various mental disorders. The revised 30-item Mystical Experience Questionnaire is one of several psychometric scales designed to evaluate such subjective experiences induced by psychedelic drugs. The field of psychedelic research is growing in Scandinavian countries, yet there is currently a lack of translated and culturally adapted Norwegian versions of rating scales for assessing psychedelic drug-induced states of consciousness. With planned and upcoming psychedelic research projects in Norway, there is a need for a Norwegian version of the MEQ30.
Aims: We aimed to translate and adapt the Revised Mystical Experiences Questionnaire (MEQ30) from English to Norwegian.
Methods: We used rigorous translation methods, including two independent forward translations, one back-translation, pilot testing on a small psychedelic user group ( n = 6) and cognitive debriefing in an expert-panel ( n = 6) to ensure a culturally adapted Norwegian translation.
Results: Our translation and adaptation procedure resulted in a final Norwegian version of the MEQ30.
Conclusion: The Norwegian MEQ30 is ready to be implemented in future Norwegian trials. Its psychometric properties have not yet been assessed.
Citations in the library
Cited by 2
Cites 32
- Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial Journal of Psychopharmacology November 30, 2016
- Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial Journal of Psychopharmacology November 30, 2016
- Trial of Psilocybin versus Escitalopram for Depression New England Journal of Medicine April 14, 2021
- Pilot Study of Psilocybin Treatment for Anxiety in Patients With Advanced-Stage Cancer Archives of General Psychiatry September 7, 2010
- Psilocybin-assisted treatment for alcohol dependence: A proof-of-concept study Journal of Psychopharmacology January 13, 2015
and 27 more in the library